An interventional study of tDCS (Transcranial Direct Current Stimulation) and tACS (Transcranial Alternating Current Stimulation) in Drug-resistant Neuropathic Pain, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies in Neuralgia with a site in France — 39 open to participants now, 40 under way, 4 of them phase 3. Neuralgia · France.
Among the 132 studies in Neuralgia with a site in France, this one is the 57th largest by planned enrollment of the 102 interventional ones that give a count, is one of 9 that started in 2025, is one of 46 with no phase, reaches primary completion later than 36 of the 39 other live ones, and was the 104th registered.
1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.
Browse Neuralgia studies →39 of the 132 studies in Neuralgia with a site in France are open now. Recruiting first, the newest first:
Hospital Ambroise Paré Paris · Sites in France
Ages 18–80
Hopitaux de Saint-Maurice · Sites in France
Ages 5–18
Poitiers University Hospital · Sites in France
Ages 18–80
Institut du Cancer de Montpellier - Val d'Aurelle · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18–85
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 34 · Phase 3 15 · Phase 4 7
First in 2001; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is close to the median of 52 across 833 interventional studies indexed under Neuralgia.
Median enrollment 62 across the 102 interventional studies, 81 across the 30 observational. Of the 82 that completed or were terminated, 8 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 132 have an industry lead sponsor. The 10 most frequent:
Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.
Hospices Civils de Lyon has 7 studies filed under Neuralgia — fewer than ten, so there is no comparison to draw.
14 of the studies in Neuralgia with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06023706Phase 3Nantes University HospitalStudy Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia. | 2027-05-08 |
| NCT04867187Centre Hospitalier Universitaire de Saint EtiennerTMS Efficacy Coupled With Mirror Therapy | 2026-12 |
| NCT06964243Institut pour la Pratique et l'Innovation en PSYchologie appliquée (Institut Pi-Psy)Protocol Assessment of Motor Cortex rTMS for Treating Neuropathic Pain | 2026-12-19 |
| NCT06250491Nadine ATTALDeep rTMS (H-coil) for Neuropathic Pain or Fibromyalgia | 2027-01-30 |
| NCT06796595UBOSGAPerioperative Medical Program to Optimize Nerve Regeneration After Robot-assisted Laparoscopic Neurolyses of Pudendal and/or Inferior Cluneal Nerves for Chronic Neuralgias: Results After 1-year Follow-up | 2027-01-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 132 studies in Neuralgia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Neuropathic pain is a public health problem with less than 50% of patients being relieved by drug treatments.
Surgically implanted motor cortex stimulation represents an invasive therapeutic solution capable of relieving a significant proportion of drug-resistant patients (1 in 2); it cannot, however, be offered to all patients, and is not morbidity-free.
Non-invasive motor cortex stimulation techniques have been refined over the last decade, in particular transcranial repetitive magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS), which provide pain relief among almost half of drug-resistant patients with few or no side effects.
To be efficient, cortical stimulation requires the activation of multiple distant networks involved in the cognitive and motivational response to pain; stimulation frequency is a crucial parameter for activating these mechanisms. The match between cortical stimulation frequency and the intrinsic neuronal frequency of the stimulated cortex has recently been suggested as a key determinant of clinical effect. Indeed, the transmission efficiency of an oscillatory network increases when its intrinsic frequency matches that of the stimulus applied to it. Given that human sensorimotor networks spontaneously oscillate at frequencies around 10 and 20 Hertz (Hz), this match could underlie the superior efficacy of transcranial stimulation at these frequencies.
The hypothesis of the study is that the analgesic effect of cortical stimulation will be enhanced if the stimulation frequency resonates with the spontaneous oscillations of the underlying cortex, thus facilitating its connectivity with the remote structures involved in pain control. The investigators propose to test this hypothesis in a population of patients with drug-resistant neuropathic pain, referred to the Pain Evaluation and Treatment Center (CETD) of the Neurological hospital, at the Hospices Civils de Lyon. The overall aim of the project is to compare the efficacy of stimulation at each individual's own rate of oscillation of the motor cortex, against a "classic" stimulation protocol, and against placebo stimulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group is made up of adult patients with drug-resistant neuropathic pain, who started with tDCS stimulation, followed by tACS stimulation, in accordance with randomization. Each series of each modality comprises 6 sessions spaced 2 weeks apart, the first session being in placebo mode and the following 5 in active mode. Each session lasts 20 minutes. In placebo mode, a 2 miliampere (mA) current is delivered for 30 seconds at the start and at the end of the session, to prevent the patient noticing the difference between placebo and active stimulation. In active mode, the 2mA current is delivered for the duration of the session.
Device: tDCS (Transcranial Direct Current Stimulation) · Device: tACS (Transcranial Alternating Current Stimulation)
This group is made up of adult patients with drug-resistant neuropathic pain, who started with tACS stimulation, followed by tDCS stimulation, in accordance with randomization. Each series of each modality comprises 6 sessions spaced 2 weeks apart, the first session being in placebo mode and the following 5 in active mode. Each session lasts 20 minutes. In placebo mode, a 2mA current is delivered for 30 seconds at the start and at the end of the session, to prevent the patient noticing the difference between placebo and active stimulation. In active mode, the 2mA current is delivered for the duration of the session.
Device: tDCS (Transcranial Direct Current Stimulation) · Device: tACS (Transcranial Alternating Current Stimulation)
The tDCS group will be treated with non-invasive motor cortex stimulation. A two-minute EEG recording will be made before each session, using the same electrodes as for stimulation. Anodal stimulation of 2,0 mA will be delivered over the motor area contralateral to the painful region (C4 or C3 according to the international 10-20 system). The return electrode will be placed over the fronto-polar region (FP1 or FP2) ipsilateral to the painful region. If pain is bilateral, the most painful region will be chosen to be treated.
The tACS group will be treated with non-invasive motor cortex stimulation. The stimulation series comprises six sessions spaced 2 weeks apart, the first session being placebo. A two-minute EEG recording will be made before each session, using the same electrodes as for stimulation. Stimulation frequency will be set according to the dominant frequency recorded over the motor area. Anodal stimulation of 2,0 mA will be delivered over the motor area contralateral to the painful region (C4 or C3 according to the international 10-20 system). The return electrode will be placed over the fronto-polar region (FP1 or FP2) ipsilateral to the painful region.
Pain intensity measure
Comparison of weekly standardized averages of the Numerical rating scale (NRS) values at the end of tACS versus tDCS versus placebo stimulation sessions. Pain scale measurement: pain scale : 1 the minimum and 10 maximum value, 10 the higher score mean a worse outcome.
Time frame: daily from the beginning until the end of the protocol (15 months)
Percentage of responding patients Percentage of patients responding favorably to stimulation (Z-score <-2) after tACS and conventional tDCS.
The response is considered favorable if on the NRS scale, compared with the baseline of each participant, there is a pain improvement of: * more than 30% or * more than 2 points or * more than 2 Standard Deviation Pain scale measurement: pain scale : 1 the minimum and 10 maximum value, 10 the higher score means a worse outcome.
Time frame: daily from the beginning until the end of the protocol (15 months)
Patient's Global Impression of Change (PGIC) Comparison of weekly standardized values of the PGIC at the end of tACS versus tDCS versus placebo stimulation sessions.
The PGIC is a seven-points scale that allows the patient to rate their overall impression of change 1 minimum value and 7 maximum value, and 7 higher score means worse result.
Time frame: one a week from the beginning until the end of the protocol (15 months)
Fatigue score Comparison of weekly standardized averages of the fatigue score values at the end of tACS versus tDCS versus placebo stimulation sessions.
The fatigue score is a ten-points (from 0 to 10) scale that allows the patient to rate their fatigue fatigue scale : 1 the minimum and 10 maximum value, 10 the higher score means a worse outcome.
Time frame: daily from the beginning until the end of the protocol (15 months)
Sleep score Comparison of weekly standardized averages of the sleep score values at the end of tACS versus tDCS versus placebo stimulation sessions.
The sleep score is a ten-points (from 0 to 10) scale that allows the patient to rate their quality of sleep with 0= bad quality and 10 = excellent quality Sleep scale : 1 the minimum and 10 maximum value, 10 the higher score means a worse outcome.
Time frame: daily from the beginning until the end of the protocol (15 months)
Sympathetic Skin Response (SSR) measurement Variation, in patients with hyperalgesia/allodynia, of Sympathetic Skin Response after treatment with tACS versus tDCS versus placebo.
SSR is an objective measure of patient's arousal. For patients suffering from allodynia, SSR will be measured after touch (brush) and/or heat (laser) stimulation on sensitized region and a symmetrical non-sensitised region SSR is expressed in mV(millivolt). It is a record of a physiological measurement. The minimum value corresponds to the absence of a response greater than the background recorded by the electrodes. There is no maximum value. The change in response is significant if there is a change greater than 30% from baseline.
Time frame: SSR will be measured in allodynic patients before each stimulation and evaluation session, starting with the first stimulation session until the end of the protocol (15 months)
Started Apr 2025 (actual). Primary completion is estimated for Jan 2029, 45 months after the start.
Of 249 non-industry interventional studies with no phase under Neuralgia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 45 months is above that.
Counting every sponsor, half of 267 studies reached it within 24 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.